Cellectis to receive European patent for CRISPR use in T-cells – pharmabiz.com
|
Cellectis to receive European patent for CRISPR use in T-cells
pharmabiz.com Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), has announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using … |
